# Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

> **NCT00049712** · PHASE1 · COMPLETED · sponsor: **University of Wisconsin, Madison**

## Conditions studied

- Lymphoma
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** etaracizumab

## Key facts

- **NCT ID:** NCT00049712
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** — (—)
- **Last updated:** 2019-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049712, "Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00049712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*